Treatments currently used for patients with myasthenia gravis (MG) include steroids, non-steroid immune suppressive agents, plasma exchange, intravenous immunoglobulin and thymectomy. Data from randomized controlled trials (RCTs) support the use of some of these therapeutic modalities and the evidence for non-surgical therapies are the subject of other Cochrane reviews. Significant uncertainty and variation persist in clinical practice regarding the potential role of thymectomy in the treatment of people with MG.
To assess the efficacy and safety of thymectomy in the management of people with non-thymomatous MG.
On 31 March 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2013, Issue 3), MEDLINE (January 1966 to March 2013), EMBASE (January 1980 to March 2013) and LILACS (January 1992 to March 2013) for RCTs. Two authors (RS and GC) read all retrieved abstracts and reviewed the full texts of potentially relevant articles. These two authors checked references of all manuscripts identified in the review to identify additional articles that were of relevance and contacted experts in the field to identify additional published and unpublished data. Where necessary, authors were contacted for further information.
Randomized or quasi-randomized controlled trials of thymectomy against no treatment or any medical treatment, and thymectomy plus medical treatment against medical treatment alone, in people with non-thymomatous MG.
We did not use measured outcomes as criteria for study selection.
Data collection and analysis
We planned that two authors would independently extract data onto a specially designed data extraction form and assess risk of bias; however, there were no included studies in the review. We would have identified any adverse effects of thymectomy from the included trials.
We did not identify any RCTs testing the efficacy of thymectomy in the treatment of MG. In the absence of data from RCTs, we were unable to do any further analysis.
There is no randomized controlled trial literature that allows meaningful conclusions about the efficacy of thymectomy on MG. Data from several class III observational studies suggest that thymectomy could be beneficial in MG. An RCT is needed to elucidate if thymectomy is useful, and to what extent, in MG.
Plain language summary
Surgical removal of the thymus for myasthenia gravis that is not caused by a tumour of the thymus
Myasthenia gravis is a disorder that causes muscle weakness and excessive muscle tiredness. In most people with myasthenia gravis, muscles throughout the body are affected in the first two years after the onset of symptoms, although there is also a form of the disease that affects only the eyes (ocular myasthenia). Myasthenia gravis occurs when the person’s own immune system attacks the vital structures that transmit impulses from nerves to muscle, the neuromuscular junctions. A tumour affecting an immune system organ called the thymus (a thymoma) is sometimes the underlying cause; this is known as thymomatous myasthenia gravis. Thymomatous myasthenia gravis was not the subject of this systematic review as the thymoma should be treated on its own merit, independently of the myasthenia gravis.
Some observational studies suggest that removal of the thymus (thymectomy) might be useful in people with myasthenia gravis who do not have a thymoma (non-thymomatous myasthenia gravis). It is generally accepted that thymectomy should not be used in ocular myasthenia, although some people think that it could be used when there is no response to medical therapy. In our systematic review of the evidence we did not find any randomized controlled trials (RCTs) of thymectomy in non-thymomatous myasthenia gravis. At present, as there is no RCT, the value of thymectomy is a subject of controversy and medical practice varies among practising physicians. An RCT is required to find out whether thymectomy is effective in generalized myasthenia gravis.